GlassScriptPhysician profile
Jon Scott Decuir
NPI 1598142150
$6,780.94
in general payments reported to CMS, 2019-2025
23 companies · $630 in 2025
The $630 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $533 · 2021: $1,673 · 2022: $1,751 · 2023: $711 · 2024: $582 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904 · Travel and Lodging: $18.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.48 |
| Travel and Lodging | $18.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,409.25 | 2019-2025 | Diamondback Coronary, Quadra Assura, Aveir |
| Cardiovascular Systems INC. | $1,065.72 | 2020-2023 | Diamondback Coronary |
| Inari Medical, INC. | $854.46 | 2021-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Shockwave Medical, INC | $578.49 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $439.94 | 2021-2025 | In.Pact Admiral, Concertotm, Closurefast |
| Stryker Corporation | $388.40 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Flowtriever |
| Boston Scientific Corporation | $323.01 | 2021-2024 | Eluvia |
| Surmodics, INC. | $248.40 | 2022 | |
| Philips North America LLC | $212.61 | 2019-2025 | Labosys, Philips Laser System, Intrasight 2 Mobile |
| Amgen INC. | $174.26 | 2019-2023 | Repatha |
| Terumo Medical Corporation | $165.24 | 2022-2023 | Angio-Seal |
| Abiomed | $163.58 | 2023-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $157.52 | 2019-2023 | Brilinta |
| Astellas Pharma US INC | $134.38 | 2019 | |
| Saranas, INC. | $109.80 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $101.91 | 2023 | Sapien 3 Ultra Resilia |
| Penumbra, INC. | $90.33 | 2024 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $89.50 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $19.08 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.82 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.19 | 2019 | |
| Atricure, INC. | $13.09 | 2021 | |
| Pfizer INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Decuir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.